AMISULPRIDE

作品数：4被引量：11H指数：2
导出分析报告
相关领域：医药卫生更多>>
相关作者：张为革更多>>
相关机构：沈阳药科大学更多>>
相关期刊：《中国药物化学杂志》《Military Medical Research》《中国药理学与毒理学杂志》《World Journal of Psychiatry》更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-4
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine‑resistant treatment‑refractory schizophrenia:a 12‑week randomized,double‑blind,placebo‑controlled trial被引量：3
《Military Medical Research》2023年第4期431-443,共13页Ming‑Huan Zhu Zhen‑Jing Liu Qiong‑Yue Hu Jia‑Yu Yang Ying Jin Na Zhu Ying Huang Dian‑Hong Shi Min‑Jia Liu Hong‑Yang Tan Lei Zhao Qin‑Yu Lv Zheng‑Hui Yi Feng‑Chun Wu Ze‑Zhi Li 
supported by the National Natural Science Foundation of China(81401127);the Clinical Research Project of Shanghai Municipal Health Commission(20204Y0173);the Open Project Program of State Key Laboratory of Virtual Reality Technology and Systems,Beihang University(VRLAB2022 B02);the Shanghai Key Laboratory of Psychotic Disorders Open Grant(21-K03);the Scientific Research Project of Traditional Chinese Medicine of Guangdong(20192070);the Guangzhou Municipal Key Discipline in Medicine(2021–2023);the Science and Technology Plan Project of Guangdong Province(2019B030316001).
Background:Although clozapine is an effective option for treatment-resistant schizophrenia(TRS),there are still 1/3 to 1/2 of TRS patients who do not respond to clozapine.The main purpose of this randomized,double-bli...
关键词：Schizophrenia Clozapine-resistant treatment-refractory schizophrenia CLOZAPINE AMISULPRIDE Augmentation 
Repetitive transcranial magnetic stimulation combined with olanzapine and amisulpride for treatment-refractory schizophrenia被引量：2
《World Journal of Psychiatry》2023年第7期453-460,共8页Jin-Ling Liu Zhi-Mei Tan Shu-Jie Jiao 
BACKGROUND Treatment-refractory schizophrenia(TRS),accounting for approximately 30%of all schizophrenia cases,has poor treatment response and prognosis despite treatment with antipsychotic drugs.AIM To analyze the the...
关键词：Repetitive transcranial magnetic stimulation OLANZAPINE AMISULPRIDE Treatment-refractory schizophrenia Therapeutic effectiveness Cognitive function 
Modeling and simulation for individualized therapy of amisulpride in Chinese patients with schizophrenia:focus on inter interindi⁃vidual variability,therapeutic reference range and laboratory alert level被引量：6
《中国药理学与毒理学杂志》2021年第9期661-662,共2页HUANG Shan-qing LI Lu WANG Zhan-zhang XIAO Tao LI Xiao-lin LIU Shu-jing ZHANG Ming LU Hao-yang WEN Yu-guan SHANG De-wei 
OBJECTIVE To explain the high inter-individual variability and the frequency of exceeding the therapeutic reference range and the laboratory alert level of amisulpride,a popula⁃tion pharmacokinetic model in Chinese pa...
关键词：AMISULPRIDE population pharmacoki⁃netics therapeutic drug monitoring modeling and simulation individualized therapy 
氨磺必利(Amisulpride,Barhemsys)
《中国药物化学杂志》2021年第2期165-165,共1页孙仲桥(编译) 张为革(审校) 
氨磺必利(amisulpride)是由 Acacia Pharma 公司开发的一种多巴胺 D2 受体拮抗剂,于 2020 年 2 月 26 日经美国 FDA 批准上市,商品名 Barhemsys。该药为注射剂,用于预防或治疗术后恶心呕吐(postoperative nausea and vomiting,PONV)[1]。
关键词：氨磺必利 术后恶心呕吐 受体拮抗剂 PONV 多巴胺 
全选清除导出
共1页<1>
检索报告 对象比较 聚类工具 使用帮助 返回顶部